7M6E image
Entry Detail
PDB ID:
7M6E
EMDB ID:
Title:
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19
Biological Source:
PDB Version:
Deposition Date:
2021-03-25
Release Date:
2021-05-05
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Mutations:R682G, R683S, R685S, F817P, A892P, A899P, A942P, K986P, V987P
Chain IDs:A, B, D (auth: E)
Chain Length:1288
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:BG10-19 Fab Light Chain
Chain IDs:G (auth: C), H (auth: G), I (auth: L)
Chain Length:216
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:BG10-19 Fab Heavy Chain
Chain IDs:C (auth: D), E (auth: F), F (auth: H)
Chain Length:231
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we combined B cell sorting with single-cell VDJ and RNA sequencing (RNA-seq) and mAb structures to characterize B cell responses against SARS-CoV-2. We show that the SARS-CoV-2-specific B cell repertoire consists of transcriptionally distinct B cell populations with cells producing potently neutralizing antibodies (nAbs) localized in two clusters that resemble memory and activated B cells. Cryo-electron microscopy structures of selected nAbs from these two clusters complexed with SARS-CoV-2 spike trimers show recognition of various receptor-binding domain (RBD) epitopes. One of these mAbs, BG10-19, locks the spike trimer in a closed conformation to potently neutralize SARS-CoV-2, the recently arising mutants B.1.1.7 and B.1.351, and SARS-CoV and cross-reacts with heterologous RBDs. Together, our results characterize transcriptional differences among SARS-CoV-2-specific B cells and uncover cross-neutralizing Ab targets that will inform immunogen and therapeutic design against coronaviruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures